Results 121 to 130 of about 780,037 (214)

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Correction to: Cost-Consequences of Adding Gliclazide Modified Release to Metformin in Patients with Uncontrolled Type 2 Diabetes in the United Arab Emirates. [PDF]

Adv Ther
Farghaly M, Cristeau O, Al Awadi F, Al Dallal S.   +3 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

pH-responsive hyaluronic acid-co-poly(acrylic acid) hydrogel scaffolds for modified release of mesalamine; characterization and biosafety evaluation. [PDF]

RSC Adv
Liaqat H, Minhas MU, Badshah SF, Barkat K, Khan S, Chopra S, Chopra H, Alyami EM, Metouekel A, Asrat Mengistie A, Elossaily GM, Shahid M.   +11 more
europepmc   +1 more source

Effects of the therapy shift from cortisone acetate to modified-release hydrocortisone in a group of patients with adrenal insufficiency. [PDF]

Front Endocrinol (Lausanne), 2023
Frigerio S, Carosi G, Ferrante E, Sala E, Polledri E, Fustinoni S, Ambrosi B, Chiodini I, Mantovani G, Morelli V, Arosio M.   +10 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Cost-Consequences of Adding Gliclazide Modified Release to Metformin in Patients with Uncontrolled Type 2 Diabetes in the United Arab Emirates. [PDF]

Adv Ther
Farghaly M, Cristeau O, Al Awadi F, Al Dallal S.   +3 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Switching Patients With Congenital Adrenal Hyperplasia to Modified-Release Hydrocortisone Capsules: Relative Bioavailability and Disease Control. [PDF]

Clin Endocrinol (Oxf)
Ross RJM, Arlt W, de la Perriere AB, Hirschberg AL, Juul A, Merke DP, Newell-Price JDC, Prete A, Rees DA, Reisch N, Stikkelbroeck M, Touraine PA, Maltby K, Quirke J, Coope H, Porter J.   +15 more
europepmc   +1 more source

Amorphization and modified release of ibuprofen by post-synthetic and solvent-free loading into tailored silica aerogels. [PDF]

Drug Deliv, 2022
Zarinwall A, Maurer V, Pierick J, Oldhues VM, Porsiel JC, Finke JH, Garnweitner G.   +6 more
europepmc   +1 more source